Sinolink Securities Co.Ltd(600109)
About Xiamen Amoytop Biotech Co.Ltd(688278)
Special verification opinions on the deposit and use of raised funds in 2021
Sinolink Securities Co.Ltd(600109) (hereinafter referred to as ” Sinolink Securities Co.Ltd(600109) ” or “sponsor”) as a sponsor of Xiamen Amoytop Biotech Co.Ltd(688278) (hereinafter referred to as ” Xiamen Amoytop Biotech Co.Ltd(688278) ,” listed company “or” company “) for initial public offering of shares and listing on the science and innovation board, According to China Securities Regulatory Commission’s “guidelines on the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies”, “Listing Rules of Shanghai Stock Exchange’s science and Innovation Board” and “guidelines on the self-discipline supervision of listed companies on Shanghai Stock Exchange’s science and innovation board No. 1 – standardized operation” and other relevant provisions, the company’s deposit and actual use of raised funds in 2021 are reported as follows:
1、 Basic information of raised funds
(I) actual amount of raised funds and receipt of funds
Approved by the reply on Approving the registration of Xiamen Amoytop Biotech Co.Ltd(688278) initial public offering (zjxk [2019] No. 2828) of China Securities Regulatory Commission and approved by the “self regulatory decision [2020] No. 21” of Shanghai Stock Exchange, the company issued 46.5 million RMB ordinary shares (A shares) to the public for the first time, with an issue price of 8.24 yuan per share, and the total funds raised this time was 383.16 million yuan, According to relevant regulations, after deducting the issuance expenses of 527137 million yuan, the net amount of funds actually raised was 3304463 million yuan. All the above raised funds have been received on January 13, 2020. Rongcheng Certified Public Accountants (special general partnership) has verified the receipt of funds and issued the capital verification report (Rongcheng Yan Zi [2020] No. 361z0003). The company has carried out special account storage management for the above raised funds. (II) use of raised funds
As of December 31, 2021, the company has used a total of 245488100 yuan of raised funds (including 1927744 million yuan of raised investment projects and 527137 million yuan of issuance expenses), 9.3355 million yuan of interest income, 50 thousand yuan of handling expenses, and the balance of raised funds is 14702400 yuan (including 60 million yuan of financial products that are not due).
2、 Management of raised funds
(I) construction of raised funds management system
In order to standardize the use and management of raised funds, the company has formulated the management system of raised funds, which has made clear provisions on the storage, use and supervision of raised funds. In the management of raised funds, the company strictly abides by the requirements of laws, regulations and normative documents such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the self discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and follows the principles of standardization, safety, efficiency and transparency.
(II) performance of tripartite supervision agreement for raised funds
On January 13, 2020, the company signed the tripartite supervision agreement on the special account storage of raised funds with the sponsor Sinolink Securities Co.Ltd(600109) and the bank with the special account for the storage of raised funds. The supervision agreement defines the rights and obligations of all parties, and the main terms of the agreement are not significantly different from the tripartite supervision agreement (model) on the special account storage of raised funds of Shanghai Stock Exchange. During the reporting period, all parties to the agreement performed their duties in accordance with the provisions of the regulatory agreement. (III) storage of raised funds in special account
As of December 31, 2021, the deposit of the company’s special account for raised funds is as follows:
Name of account opening bank balance of special account for raised funds of special fund-raising investment project
Name account number (10000 yuan)
China Merchants Bank Co.Ltd(600036) shares have 59290262711 protein drug production reform
Xiamen Branch 0508 expansion and R & D center construction 404373
Xiamen tezhenhai sub branch establishment project
Baobio China China Construction Bank Corporation(601939) shares 35150198110
Xiamen 1 Shenzhen Tellus Holding Co.Ltd(000025) 02 new drug R & D project of Engineering Co., Ltd. 415278
Haicang sub branch
The company Industrial Bank Co.Ltd(601166) shares have clinical experience of chronic hepatitis B
Xiamen Haicang 12994010010503.73
Sub branch 0357161 cure research project
Total 870024
Note: as of December 31, 2021, the company used some idle raised funds for cash management, and the amount not yet due was 60 million yuan.
3、 Actual use of raised funds in 2021
(I) use of funds for projects invested with raised funds
During the reporting period, the actual use of the company’s raised funds is detailed in Schedule 1 “comparison table of the use of raised funds in 2021”.
(II) early investment and replacement of raised investment projects
On March 27, 2020, the company held the 14th meeting of the 7th board of directors and the 10th meeting of the 7th board of supervisors respectively, deliberated and approved the proposal on replacing the self raised funds invested in advance with the raised funds, and agreed to use the raised funds of 698005 million yuan to replace the self raised funds of the pre invested projects and the paid issuance expenses. The replacement work does not change the purpose of the company’s raised funds in a disguised manner, and the replacement time is less than 6 months from the arrival time of the raised funds, which meets the regulatory requirements. The independent directors and the recommendation institution of the company have expressed their explicit consent to the above matters. Rongcheng Certified Public Accountants (special general partnership) verified the above replacement matters and issued the verification report on Xiamen Amoytop Biotech Co.Ltd(688278) using self raised funds to invest in raised funds investment projects in advance and pay issuance expenses (Rongcheng zhuanzi [2020] No. 361z0167).
